Abstract 4325
Background
Osimertinib (osi) is a third-generation EGFR-TKI selective for sensitizing (EGFRm) and p.T790M resistance mutations approved for metastatic NSCLC. Despite a primary benefit, almost all patients (pts) develop acquired resistance, whose mechanisms are not completely characterized.
Methods
Metastatic NSCLC pts who performed a tissue and plasma biopsy at osi progression, and optionally before, were identified from the prospective MATCH-R trial (NCT02517892). Targeted next-generation sequencing (NGS, 74 to 82 genes), comparative genomic hybridization (CGH), whole exome sequencing (WES), and RNA sequencing (RNA-Seq) were performed on the tissue. All molecular alterations were reviewed, those related to definitive or potential resistance mechanism were included in the analysis.
Results
The 31 pts included (23 [74%] women) had the tissue biopsy analysis at osi progression by NGS (97%), CGH (87%) and WES+RNA-Seq (61%). Additional cfDNA genomic profile was available for 17 pts (55%). Two pts received osi as first-line and 29 (94%) at previous EGFR TKI resistance. Most frequent acquired resistance to osi was EGFR on-target alterations (n = 12, 39%): 9 p.C797S, 2 p.L817Q and 1 EGFR amplification (amp). 4 pts (3 p.C797S and 1 p.L817Q) also had EGFR amp as potential concurrent resistance. Off-target resistance alterations were found in 11 (35%) tumors: 5 fusions involving oncogenes (16%, RET, MET, BRAF, ALK, FGFR3, and NTRK1), 2 with BRAF p.V600E mutation (6%) which co-occurred with p.C797S, then MET amp, HER2 amp, KRAS mut, and PIK3CA mut in 1 (3%). More than one resistance mechanism was found in 14 tumors (45%), more than two in 5 (16%). DNA repair gene alterations were observed in 10 pts (32%). Median TMB, assessed in 18 tumors, was 2.52 mutations/Mb, 1 was classified as high. p.T790M loss (54%) was associated with a more aggressive progression pattern compared with p.T790M maintain. For 20 pts a paired pre-osi biopsy was analyzed; 4 alterations (20%, 1 on-target, 3 off-target) were already detected.
Conclusions
Resistance mechanisms to osi are more complex than expected since more than one alteration was recognized in 45% of pts. Combination strategy might be needed.
Clinical trial identification
NCT02517892.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Diego Enrico was recipient of the grant DUERTECC (Diplôme Universitaire Européen de Recherche Translationnelle et Clinique en Cancérologie) for 2018-2019.
Disclosure
Y. Loriot: Honoraria (self): Roche, MSD, Astellas, Janssen, AstraZeneca, BMS, Seattle Genetics, Sanofi, Clovis, Pfizer; Honoraria (institution): Roche, MSD, Astellas, Janssen, AstraZeneca, BMS, Seattle Genetics, Sanofi, Clovis, Incyte, Pfizer; Research grant / Funding (institution): Roche, MSD, Sanofi; Travel / Accommodation / Expenses: Roche, MSD, Janssen, AstraZeneca, Seattle Genetics,; Licensing / Royalties: Pending patent (USA 62/455211, Europe 17209098.7). D. Planchard: Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, MedImmune, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; Research grant / Funding (institution): AstraZeneca, Bristol-Myers Squibb, AbbVie, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo; Travel / Accommodation / Expenses: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim , Roche, Merck,Novartis, prIME Oncology, Pfizer. S. Michiels: Advisory / Consultancy, Statistical advice : Janssen Cilag France; Advisory / Consultancy, Data and safety monitoring member : Hexal, J&J, Ipsen, Neovacs, Genticel, Mabxience, Steba, IQVIA, Roche, Sensorion, Biophytis . C. Massard: Leadership role: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Bristol; Research grant / Funding (institution): Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; Non-remunerated activity/ies: Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuiX, Pfizer, Roche; Advisory / Consultancy: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Novartis, Pfizer, Roche, Sanofi, Orion . J. Soria: Advisory / Consultancy: AstraZeneca, BMS, Merck, Pfi zer/Merck Serono, and Roche; Full / Part-time employment: AstraZeneca; Shareholder / Stockholder / Stock options: AstraZeneca. F. André: Research grant / Funding (institution): NVS, AZ, Roche, Daiichi, Lilly, Pfizer. B. Besse: Research grant / Funding (institution): AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma. All other authors have declared no conflicts of interest.
Resources from the same session
3993 - Prophylaxis with Lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: results from the German NIS NADENS
Presenter: Marion Kiechle
Session: Poster Display session 1
Resources:
Abstract
3471 - Randomized phase 2 trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients.
Presenter: Florian Clatot
Session: Poster Display session 1
Resources:
Abstract
1327 - Simultaneous intravenous fluid infusion to prevent oxaliplatin infusion-related venous pain
Presenter: Stefan Van Ravensteijn
Session: Poster Display session 1
Resources:
Abstract
5004 - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project.
Presenter: Enrique Aranda Aguilar
Session: Poster Display session 1
Resources:
Abstract
2222 - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response.
Presenter: Manuel Cobo Dols
Session: Poster Display session 1
Resources:
Abstract
5556 - Consensus on strategies in the management of opioid-induced constipation in cancer patients
Presenter: Regina Girones Sarrio
Session: Poster Display session 1
Resources:
Abstract
3913 - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Presenter: Yanni Lou
Session: Poster Display session 1
Resources:
Abstract
2208 - A prospective study about the complementary medicine among patients with cancers
Presenter: Wala Ben Kridis
Session: Poster Display session 1
Resources:
Abstract
1082 - Prevalence and management of Potentially Inappropriate Medication use and Potential Omissions in Medication in older cancer patients - the PIM POM study
Presenter: Fianne van Loveren
Session: Poster Display session 1
Resources:
Abstract
1701 - Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer : A randomized controlled trial
Presenter: Wonyoung Choi
Session: Poster Display session 1
Resources:
Abstract